Serum Markers of Epithelial Mesenchymal Transition as Predictors of HCV-induced Liver Fibrosis, Cirrhosis and Hepatocellular Carcinoma
Keywords:
Liver Fibrosis, Transforming Growth Factor-Beta (TGF-β), Bone Morphogenic Protein (BMP)-7, Connective Tissue Growth Factor (CTGF), YKL-40Abstract
Introduction: Hepatitis C virus (HCV) is a major cause of chronic liver disease in Egypt, leading to hepatic fibrosis, liver cirrhosis (LC), and hepatocellular carcinoma (HCC). Liver fibrosis is characterized by excessive deposition of extracellular matrix (ECM). Newly-recognized pathogenic mechanisms point to the epithelial-mesenchymal transition (EMT) of hepatocytes to matrix synthesizing (myo-) fibroblasts. Transforming growth factor-beta (TGF-β1), bone morphogenic protein (BMP)-7, and connective tissue growth factor (CTGF) are biomarkers reflecting the EMT process. YKL-40 is a glycoprotein member of ECM and plays a role in cancer cell proliferation. The purpose of this study was to determine the serum biomarkers of EMT and its impact on the fibrogenic process and tumorigenesis in HCV-genotype 4 patients.
Methods: In this case-control study that was conducted in 2013-2014, 97 HCV-infected patients were subjected to clinical examination, laboratory investigations, and liver biopsy. According to the histopathologic examination, they were classified to F0 (14 cases), F1 (17 cases), F2 (15 cases), F3 (18 cases), F4 (22 cases), and HCC (11 cases). Fifteen age- and gender-matched subjects were included as normal controls. Serum levels of TGF-β1, BMP-7, CTGF, YKL-40 were assessed, and the TGF-β1/BMP-7 ratios were calculated. The data were analyzed by plotting the receiver operating characteristic curve (ROC), Pearson product-moment correlation coefficient, and Spearman's rank correlation coefficient (Spearman's rho).
Results: Serum levels of TGF-β1, BMP-7, CTGF, and YKL-40 were significantly increased in all patient groups compared to controls (p < 0.001). LC exhibited the highest CTGF level and YKL-40 was highest in HCC. The TGF-β1/ BMP-7 ratios reflected the progression of EMT from CHC to LC, however, there was no significant difference between LC and HCC. TGF-β1/ BMP-7 ratio is considered to reflect positive correlation with CTGF in LC group (r = 0.629; p < 0.03) and YKL-40 in HCC group (r = 0.504; p < 0.04).
Conclusion: Increased TGF-β1/BMP-7 ratio and CTGF levels reflect the rate of EMT and provide information about fibrogenic activity. Also, this ratio, in association with YKL-40, can be used to predict malignant transformation in HCV-genotype 4 Egyptian patients.
References
Mahmoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in
Egypt: a systematic review and data synthesis. BMC Infect Dis. 2013; 13: 288. doi: 10.1186/1471-2334-13- 288, PMID: 23799878 , PMCID: PMC3702438.
Ahram Online. Fact box: 15 facts about Hepatitis C in Egypt and the latest approved drugs. 15th Annual
Congress of the Egyptian Society of Hepatology, Gastroenterology and Infectious Diseases. Ahram Online
used the recommendations of the panel, along with information from the Egyptian Ministry of Health and
World Health Organization (WHO) Ingy Deif, Cairo, Thursday 29 May 2014.
Averhoff FM, Glass N, Holtzman D. Global burden of Hepatitis C: Considerations for healthcare providers
in the United States. Clin Infect Dis. 2012; 55(1): 10-15. doi: 10.1093/cid/cis361, PMID: 22715208.
Andrade LJO, Junior AD, Melo RC, De Souza EC, Silva CAC, Paraná R. Association between Hepatitis
C and Hepatocellular Carcinoma. J Glob Infect Dis. 2009; 1(1):33-7. doi: 10.4103/0974-777X.52979,
PMID: 20300384 , PMCID: PMC2840947.
Gressner OA, Rizk MS, Kovalenko E, Weiskirchen R, Gressner AM. Changing the pathogenetic roadmap
of liver fibrosis? Where did it start; where will it go? J Gastroenterol Hepathol. 2008; 23:1024-35. doi:
1111/j.1440-1746.2008.05345.x , PMID: 18505415.
Gressner OA, Gressner AM . Connective tissue growth factor: a fibrogenic master switch in fibrotic liver
diseases. Liver Int. 2008; 28: 1065-79. doi: 10.1111/j.1478-3231.2008.01826.x, PMID: 18783549
Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling,
fibroses and cancer. Dan Med Bull. 2006; 53:172-209. PMID: 17087877.
Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in
liver: a short survey. World J Gastroenterol. 2009; 15: 2433-2440. doi: 10.3748/wjg.15.2433, PMID:
, PMCID: PMC2686898
Xiao XQ, Hassanein T, Li QF, Liu W, Zheng YH, Chen J. YKL-40 expression in human hepatocellular
carcinoma: a potential biomarker? Hepatobiliary Pancreat Dis Int. 2011; 10: 605-10. doi: 10.1016/S1499- 3872(11)60103-3.
Gressner AM, Yagmur E, Lahme B, Gressner O, Stanzel S. Connective tissue growth factor in serum as a
new candidate test for assessment of hepatic fibrosis. Clin Chem. 2006; 52: 1815-17. doi:
1373/clinchem.2006.070466, PMID: 16858074.
Friedman SL. Mechanisms of hepatic fibrogenesis, Gastroenterology. 2008; 134(6): 1655-69. doi:
1053/j.gastro.2008.03.003, PMID: 18471545 , PMCID: PMC2888539.
Pegorier S, Campbell GA, Kay AB, Lloyd CM. Bone morphogenetic protein (BMP)-4 and BMP-7 regulate
differentially transforming growth factor (TGF)-beta1 in normal human lung fibroblasts (NHLF). Respir
Res. 2010; 11: 85. doi: 10.1186/1465-9921-11-85, PMID: 20573231, PMCID: PMC2898775
Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol
Res. 2003; 26:1-9. doi: 10.1016/S1386-6346(03)00115-3
Gressner O, Weiskirchen R, Gressener AM. Evolving concepts of liver fibrogenesis provide new diagnostic
and therapeutic options. Comp Hepatol. 2007; 6:7-20. doi: 10.1186/1476-5926-6-7, PMID: :17663771 ,
PMCID: PMC1994681.
Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates
cell signaling by BMP and TGF-beta. Nat Cell Biol. 2002; 4:599-604, PMID: 12134160, PMCID:
PMC2387275.
Choi SS, Diehl AM. Epithelial-to-mesenchymal transitions in the liver. Hepatology 2009; 50:2007-13. doi:
1002/hep.23196, PMID: 19824076, PMCID: PMC2787916.
Schiavon LL, Narciso-Schiavon JL and de Carvalho-Filho RJ: Noninvasive diagnosis of liver fibrosis in
chronic hepatitis C. World J Gastroenterol. 2014; 20: 2854-66. doi: 10.3748/wjg.v20.i11.2854, PMID:
, PMCID: PMC3961992.
Thiery JP, Acloque H, Huang RY. Epithelial mesenchymal transitions in development and disease. Cell.
; 139: 871-90. doi: 10.1016/j.cell.2009.11.007, PMID: 19945376.
Soto-Gutierrez A, Navarro-Alvarez N, Kobayashi N. Molecular pathology of liver diseases: Hepatocytes.
Molecular Pathology Library. 2010; 5:17-26. doi: 10.1007/978-1-4419-7107-4_3.
Meng XM, Chung ACK, Lan HY. Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Clin Sci.
; 124: 243-54. doi: 10.1042/CS20120252, PMID: 23126427.
W.R. Bi1, G.T. Xu2, L.X. Lv2, C.Q. Yang. The ratio of transforming growth factor-β1/Bone
morphogenetic protein-7 in the progression of the epithelial mesenchymal transition contributes to rat liver
fibrosis. Genet. Mol Res. 2014; 13(1): 1005-14. doi: 10.4238/2014.February.20.2
Nassef YE, Shady MM, Galal EM, Hamed MA. Performance of diagnostic biomarkers in predicting liver
fibrosis among hepatitis C virus-infected Egyptian children. Mem Inst Oswaldo Cruz. 2013; 108: 887-93.
doi: 10.1590/0074-0276130139, PMID: 24141960, PMCID: PMC3970648.
Divella R, Daniele A, Gadaleta C, et al. Circulating transforming growth factor-β and epidermal growth
factor receptor as related to virus infection in liver carcinogenesis. Anticancer Res. 2012; 32:141-45,
PMID: 22213299.
Neuman MG1, Benhamou JP, Bourliere M, Ibrahim A, Malkiewicz I, Asselah T et al. Serum tumor
necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are
immunomodulated by therapy. Cytokine. 2002; 17: 108-17. doi: 10.1006/cyto.2001.0997, PMID:
Iagoda AB, Koroĭ PV, Geĭvandova NI, Nikitina OA, Kastornaia IV. Growth factors and the hystologic
picture of the liver in chronic viral hepatitis and hepatic cirrhosis. Klin Med (Mosk). 2006; 84(4): 44-7.
Luo R, Yang S, Xie J, Zhao Z, He Y, Yao J. Diagnostic value of five serum markers for liver fibrosis.
Zhonghua Gan Zang Bing Za Zhi. 2001; 9: 148-150, PMID: 11412388.
Abdel-Ghaffar TY, Behairy BE, El-Shaheed A, Tawhida Y, Karam Mahdy, Mohamed El et al. Clinical
benefits of biochemical markers of fibrosis in Egyptian children with chronic liver diseases. Gastroenterol
Res. 2010; 3:262-71. doi: 10.4021/gr246w.
Nawar EA, Abul-fadl AM, Hassanin BE, Abd El Haie OM, EL-Tokhy M. Clinical value of transforming
growth factor beta as a marker of fibrosis in adolescents with chronic liver diseases. J American Science.
; 7(3): 464-71.
Chen BL, Peng J, Li QF, Yang M, Wang Y, Chen W. Exogenous bone morphogenetic protein-7 reduces
hepatic fibrosis in Schistosoma japonicum-infected mice via transforming growth factor-β/Smad signaling.
World J Gastroenterol. 2013; 19:1405-15. doi: 10.3748/wjg.v19.i9.1405, PMID: 23539268, PMCID:
PMC3602500.
Demir N1, Kolgelier S, Inkaya AC, Sumer S, Demir LS, Pehlivan FS, et al. Are bone morphogenetic
protein-7 (BMP-7) serum levels correlated with development of hepatic fibrosis? J Infect Dev Ctries. 2014;
(5):605-10, PMID: 24820464.
Sakamoto N, Yoshimura M, Kimura T, Toyama K, Sekine-Osajima Y, Watanabe M, et al. Bone
morphogenetic protein-7 and interferon-alpha synergistically suppress hepatitis C virus replicon. Biochem
Biophys Res Commun. 2007; 357(2): 467-73. doi: 10.1016/j.bbrc.2007.03.167, PMID: 17433261.
Weiskirchen R, Meurer SK, Gressner OA, Herrmann J, Borkham-Kamphorst E, Gressner AM. BMP-7 as
antagonist of organ fibrosis. Front Biosci (Landmark Ed). 2009; 14: 4992-5012. doi: 10.2741/3583, PMID:
Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, et al. BMP-7 counteracts TGF- beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 2003; 9(7):
-8. doi: 10.1038/nm888, PMID: 12808448.
Kinoshita K1, Iimuro Y, Otogawa K, Saika S, Inagaki Y, Nakajima Y, et al. Adenovirus-mediated
expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut. 2007; 56(5): 706-14. doi:
1136/gut.2006.092460, PMID: 17127702 , PMCID: PMC1942155.
Tacke F, Gäbele E, Bataille F, Robert F. Schwabe, Hellerbran C, et al. Bone morphogenetic protein 7 is
elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells.
Dig Dis Sci. 2007; 52(12): 3404-15. doi: 10.1007/s10620-007-9758-8, PMID: 17415633.
Cao H, Shu X, Chen LB, Zhang K, Xu QH, Li G. The relationship of expression of BMP-7 in the liver and
hepatic inflammation and fibrosis in patients with chronic HBV infection. Zhonghua Shi Yan He Lin
Chuang Bing Du Xue Za Zhi. 2010; 24(2): 101-3, PMID: 21110425.
Akdoğan MF, Azak A, Huddam B, Sakaci M, Kocak G, Denizli N, et al. Influence of bone morphogenic
protein 7 (bmp7) on the progression of chronic kidney disease. J Nephrol Urol Res. 2014; 2(1): 1-8. doi:
12970/2310-984X.2014.02.01.1.
Gressner OA, Gao C. Monitoring fibrogenic progression in the liver. Clin Chim Acta. 2014; 433: 111-22.
doi: 10.1016/j.cca.2014.02.021, PMID: 24607331.
Wong MG, Perkovic V, Woodward M, Chalmers J, Li Q, Hillis GS et al. Circulating bone morphogenetic
protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2
diabetes mellitus. Kidney Int, 2013;83: 278-84. doi: 10.1038/ki.2012.383, PMID: 23235570
Stumm CL, Halcsik E, Landgraf RG, Camara NO, Sogayar MC, Jancar S. Lung remodeling in a mouse
model of asthma involves a balance between TGF-β1 and BMP-7. PLoS One, 2014; 9(4): e95959. doi:
1371/journal.pone.0095959, PMID: 24781156 , PMCID: PMC4004563.
Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling modulators emerge from
the bunker. J Cell Sci. 2006; 119: 4803-10. doi: 10.1242/jcs.03270, PMID: 17130294.
Jou J, Diehl AM. Epithelial-mesenchymal transitions and hepatocarcinogenesis. J Clin Invest. 2010; 120:
-4. doi: 10.1172/JCI42615, PMID: 20335655, PMCID: PMC2846072.
Piao RL, Brigstock DR, Zhu J, Zhang ML, Gao RP. Clinical significance of connective tissue growth factor
in hepatitis B virus-induced hepatic fibrosis. World J Gastroenterol. 2012; 18: 2280-6. doi:
3748/wjg.v18.i18.2280, PMID: 22611323, PMCID: PMC3351780.
Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology, 2012; 56:
-75. doi: 10.1002/hep.25670, PMID: 22378017 , PMCID: PMC4087159.
Dendooven A, Gerritsen KG, Nguyen TQ, Kok RJ, Goldschmeding R. Connective tissue growth factor
(CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers. 2011; 16: 289-301. doi:
3109/1354750X.2011.561366, PMID: 21595567.
Weng HL, Ciuclan L, Liu Y, Hamzavi J, Godoy P, Gaitantzi H, et al. Profibrogenic transforming growth
factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in
hepatocytes. Hepatology. 2007; 46: 1257-70. doi: 10.1002/hep.21806, PMID: 17657819.
Guo-Qiu W, Nai-Feng L, Xiao-Bo V, Linxian L, Chen Z, Lixia G, et al. The level of connective tissue
growth factor in sera of patients with hepatitis B virus strongly correlates with stage of hepatic fibrosis.
Viral Immunol. 2010; 23: 71-8. doi: 10.1089/vim.2009.0067, PMID: 20121404.
Gressner OA, Fang M, Li H, Lu LG, Gressner AM, Gao CF. Connective tissue growth factor
(CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients
with chronic hepatitis B infection. Clin Chim Acta. 2013; 421: 126-31. doi: 10.1016/j.cca.2013.02.029,
PMID: 23501329.
Novo E, Cannito S, Zamara E, Valfrè di Bonzo L, Caligiuri A, Cravanzola C, et al. Proangiogenic
cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol.
; 170: 1942-53. doi: 10.2353/ajpath.2007.060887, PMID: 17525262, PMCID: PMC1899450.
Yang H, Huang Y, Chen X, Liu J, Lu Y, Bu L, et al. The role of CTGF in the diabetic rat retina and its
relationship with VEGF and TGF-β(2), elucidated by treatment with CTGF siRNA. Acta Ophthalmol.
; 88: 652-9. doi: 10.1111/j.1755-3768.2009.01641.x, PMID: 20039857.
Liu FY, Xiao L, Peng YM, Duan SB, Liu H, Liu YH, et al. Inhibition effect of small interfering RNA of
connective tissue growth factor on the expression of vascular endothelial growth factor and connective
tissue growth factor in cultured human peritoneal mesothelial cells. Chin Med J. 2007; 120: 231-6. PMID:
El-Bassiouni NE, Nosseir MM, Madkour ME, Zoheiry MM, Bekheit IW, Ibrahim RA, et al. Role of
fibrogenic markers in chronic hepatitis C and associated hepatocellular carcinoma. Mol Biol Rep. 2012; 39:
-50. doi: 10.1007/s11033-012-1509-z, PMID: 22318548.
Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, et al. Serum fibrosis
markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
Gut. 2010; 59: 1401-9. doi: 10.1136/gut.2010.207423, PMID: 20675691, PMCID: PMC3740000.
Berres ML, Papen S, Pauels K, Schmitz P, Zaldivar MM, Hellerbrand C, et al. A functional variation in
CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C
infection. J Hepatol. 2009; 50: 370-6. doi: 10.1016/j.jhep.2008.09.016, PMID: 19070929.
Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, et al. Noninvasive
estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in
patients with HCV-associated liver disease. World J Gastroenterol. 2005; 11: 476-81. doi:
3748/wjg.v11.i4.476. , PMID: 15641129, PMCID: PMC4250794.
Pungpapong S, Nunes DP, Krishna M, Nakhleh R, Chambers K, Ghabril M, et al. Serum fibrosis markers
can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl. 2008; 14:
-302. doi: 10.1002/lt.21508, PMID: 18756457.
Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40 a potential new cancer biomarker? Future Oncol.
; 5: 1065-82. doi: 10.2217/fon.09.66, PMID: 19792974.
Horbinski C, Wang G, Wiley CA. YKL-40 is directly produced by tumor cells and is inversely linked to
EGFR in glioblastomas. Int J Clin Exp Pathol. 2010; 3:226-237, PMID: 20224722, PMCID: PMC2836500
Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of
hepatocellular carcinoma. Dig Dis Sci. 2010; 55: 2744-55. doi: 10.1007/s10620-010-1184-7, PMID:
Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, et al. Elevated pretreatment serum
concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with
metastatic non-small cell lung cancer. Cancer. 2010; 116: 4114-421. doi: 10.1002/cncr.25196, PMID:
Pizano-Martinez O, Yañez-Sánchez I, Alatorre-Carranza P, Miranda-Díaz A, Ortiz-Lazareno PC, GarcíaIglesias T, et al. YKL-40 expression in CD14+ liver cells in acute and chronic injury. World J
Gastroenterol. 2011; 17: 3830-5. doi: 10.3748/wjg.v17.i33.3830, PMID: 21987626, PMCID:
PMC3181445.
Rath T, Roderfeld M, Güler C, Wenzel C, Graf J, Beitinger F, et al. YKL-40 and transient elastography, a
powerful team to assess hepatic fibrosis. Scand J Gastroenterol. 2011; 46: 1369-80. doi:
3109/00365521.2011.613949, PMID: 21905976.
Zhu CB, Wang C, Chen LL, Ma GL, Zhang SC, Su L, et al. Serum YKL-40 independently predicts
outcome after transcatheter arterial chemoembolization of hepatocellular carcinoma. PLoS One. 2012; 7(9):
e44648. doi: 10.1371/journal.pone.0044648, PMID: 22970277, PMCID: PMC3435289.
Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, et al. YKL-40 expression is associated
with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res. 2005;
:3326-3334. doi: 10.1158/1078-0432.CCR-04-1765, PMID: 15867231.
Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, et al. Targeting the transforming
growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer. 2010; 9: 122.
doi: 10.1186/1476-4598-9-122, PMID: 20504320, PMCID: PMC2890606.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
